Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist
Source abstract
Abstract
Agonists of the stimulator of interferon gene (STING) are considered as promising therapeutics for cancer immunotherapy. However, drug-delivery barriers and adverse effects limit the clinical application of STING agonists. Therefore, it is an urgent need to develop an ideal delivery system to deliver STING agonists and avoid side effects. Here, we discovered that STING agonists significantly stimulated type I interferon (IFN) secretion in Clec9a+ dendritic cells (DCs). Then, we designed an engineered peptide-expressed biomimetic cancer cell membrane (EPBM)-coated nanovaccine drug-delivery system (PLGA/STING@EPBM) to deliver STING agonists and tumor antigens to Clec9a+ DCs. The PLGA/STING@EPBM nanovaccine significantly enhanced IFN-stimulated expression of genes and antigen cross-presentation of Clec9a+ DCs, thus eliciting strong antitumor effects in both anti-PD-1-responsive and -resistant tumor models without obvious cytotoxicity. Moreover, the PLGA/STING@EPBM nanovaccine combined with radiotherapy exhibited remarkable synergistic antitumor effects. Our work highlights the great potential of a EPBM-coated nanovaccine for systemic STING agonist delivery as an attractive tool for cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: interferon and immune responses · Immunotherapy and Immune Responses · Virus-based gene therapy research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China
School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China
Henan Key Laboratory of Bioactive Macromolecules, Zhengzhou University, Zhengzhou 450001, China
International Joint Laboratory for Protein and Peptide Drugs of Henan Province, Zhengzhou University, Zhengzhou 450001, China
Funding
National Natural Science Foundation of China · Guangdong Province · Shenzhen Science and Technology Program
References (56)
Show source-provided references
1. 10.1038/s41568-019-0186-910.1038/s41568-019-0186-9 ↗
2. 10.1039/C8CS00896E10.1039/C8CS00896E ↗
3. 10.1016/j.addr.2019.05.00710.1016/j.addr.2019.05.007 ↗
4. 10.1158/2326-6066.CIR-18-027710.1158/2326-6066.CIR-18-0277 ↗
5. 10.1126/science.abc662210.1126/science.abc6622 ↗
6. 10.1186/s13045-020-00862-w10.1186/s13045-020-00862-w ↗
7. 10.1002/adfm.20190662310.1002/adfm.201906623 ↗
8. 10.1016/j.drudis.2019.11.00710.1016/j.drudis.2019.11.007 ↗
9. 10.1186/s12943-019-1087-y10.1186/s12943-019-1087-y ↗
10. 10.1038/s41422-020-00395-410.1038/s41422-020-00395-4 ↗
11. 10.1172/JCI8689210.1172/JCI86892 ↗
12. 10.1186/s40425-018-0422-y10.1186/s40425-018-0422-y ↗
13. 10.1111/imr.1276510.1111/imr.12765 ↗
14. 10.1038/s41586-018-0705-y10.1038/s41586-018-0705-y ↗
15. 10.1038/s41565-018-0342-510.1038/s41565-018-0342-5 ↗
16. 10.1002/adbi.20160001310.1002/adbi.201600013 ↗
17. 10.1126/science.aba609810.1126/science.aba6098 ↗
18. 10.1126/science.abb425510.1126/science.abb4255 ↗
19. 10.1016/j.biomaterials.2020.12054210.1016/j.biomaterials.2020.120542 ↗
20. 10.1136/jitc-2019-00028210.1136/jitc-2019-000282 ↗
21. 10.1146/annurev-immunol-020711-07495010.1146/annurev-immunol-020711-074950 ↗
22. 10.1016/j.immuni.2012.04.01210.1016/j.immuni.2012.04.012 ↗
23. 10.1172/JCI3458410.1172/JCI34584 ↗
24. 10.7150/thno.5640610.7150/thno.56406 ↗
25. 10.1021/acsnano.5b0104210.1021/acsnano.5b01042 ↗
26. 10.1126/science.aau081010.1126/science.aau0810 ↗
27. 10.1126/scitranslmed.aav852110.1126/scitranslmed.aav8521 ↗
28. 10.1021/acs.nanolett.0c0398210.1021/acs.nanolett.0c03982 ↗
29. 10.1021/acsnano.0c0377610.1021/acsnano.0c03776 ↗
30. 10.18632/oncotarget.962410.18632/oncotarget.9624 ↗
31. 10.1016/j.immuni.2019.10.00910.1016/j.immuni.2019.10.009 ↗
32. 10.1158/0008-5472.CAN-15-188510.1158/0008-5472.CAN-15-1885 ↗
33. 10.1016/j.bbrc.2005.01.09310.1016/j.bbrc.2005.01.093 ↗
34. 10.1038/srep1904910.1038/srep19049 ↗
35. 10.1186/s40425-019-0654-510.1186/s40425-019-0654-5 ↗
36. 10.1016/S1470-2045(20)30271-010.1016/S1470-2045(20)30271-0 ↗
37. 10.1016/j.ccell.2016.02.00410.1016/j.ccell.2016.02.004 ↗
38. 10.1002/anie.20200278310.1002/anie.202002783 ↗
39. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
40. 10.4049/jimmunol.180.5.313210.4049/jimmunol.180.5.3132 ↗
41. 10.1186/s13045-019-0721-x10.1186/s13045-019-0721-x ↗
42. 10.1038/s41551-020-00675-910.1038/s41551-020-00675-9 ↗
43. 10.1038/nmat377510.1038/nmat3775 ↗
44. 10.1126/scitranslmed.300376310.1126/scitranslmed.3003763 ↗
45. 10.3389/fbioe.2020.0094310.3389/fbioe.2020.00943 ↗
46. 10.1158/2159-8290.CD-19-076110.1158/2159-8290.CD-19-0761 ↗
47. 10.7150/thno.3757410.7150/thno.37574 ↗
48. 10.1016/j.apsb.2017.11.00910.1016/j.apsb.2017.11.009 ↗
49. 10.1021/acsnano.7b0904110.1021/acsnano.7b09041 ↗
50. 10.1002/adma.20180717510.1002/adma.201807175 ↗
51. 10.3389/fimmu.2018.0282110.3389/fimmu.2018.02821 ↗
52. 10.1002/anie.20150622510.1002/anie.201506225 ↗
53. 10.1136/jitc-2020-00090510.1136/jitc-2020-000905 ↗
54. 10.1016/j.apsb.2020.01.00510.1016/j.apsb.2020.01.005 ↗
55. 10.1182/blood-2009-02-20687010.1182/blood-2009-02-206870 ↗
56. 10.1038/nrc395810.1038/nrc3958 ↗